Life Sciences Tools and Services

Inotiv

Inotiv Inc. and VUGENE partner to drive AI-powered drug discovery

Inotiv Inc. Outlines Growth Strategy and Operational Optimization

Inotiv released FY2025 Q4 earnings on December 3 After-Market EST, actual revenue USD 138.14 M (forecast USD 137.5 M), actual EPS USD -0.25 (forecast USD -0.46)

Inotiv released FY2025 Annual Earnings on December 3 After-Market EST, actual revenue USD 513.02 M (forecast USD 512.4 M), actual EPS USD -2.1146 (forecast USD -2.34)

Inotiv to Release FY2025 Q4 Earnings on December 3 After-Market EST, Forecast Revenue USD 137.5 M, EPS USD -0.46

Lake Street Analyst Reiterates Buy Rating on Inotiv

Inotiv released FY2025 9 Months Earnings on August 6 After-Market EST, with actual revenue of USD 374.88 M and EPS of USD -1.9716

Inotiv released FY2025 Q3 earnings on August 6 After-Market (EST), actual revenue USD 130.68 M (forecast USD 127.05 M), actual EPS USD -0.5116 (forecast USD -0.515)

Inotiv to Release FY2025 Q3 Earnings on August 6 After-Market EST, Forecast Revenue USD 127.05 M, EPS USD -0.515

Lake Street Maintains Inotiv at Buy, Cuts Price Target to $5

Inotiv released FY2025 Q2 earnings on May 7 After-Market EST, actual revenue USD 124.32 M (forecast USD 123.96 M), actual EPS USD -0.44 (forecast USD -0.635)

Inotiv released FY2025 Semi-Annual earnings on May 7 After-Market EST, actual revenue USD 244.2 M, actual EPS USD -1.3914

Inotiv Reports Q2 2025 Earnings with Revenue Growth and Narrowed Losses

Inotiv Inc Expected to Report a Loss of 63 Cents per Share for Q1 2025

Inotiv to release FY2025 Q2 earnings report on May 7 After-Market EST, forecast revenue USD 123.96 M, EPS USD -0.635

Inotiv released FY2025 Q1 earnings on February 5 After-Market (EST), actual revenue $119.88M (forecast $121.83M), actual EPS -$1.02 (forecast -$0.95)

Inotiv Inc Expects a Loss of 95 Cents per Share and a 10.1% Decline in Quarterly Revenue in 2024

Inotiv to Release FY2025 Q1 Earnings on February 5 After-Market EST, Forecast Revenue 122.74 M USD, EPS -0.95 USD

Inotiv released FY2024 Q4 earnings on December 3, 2024, after-market (EST): Actual Revenue $130.42M (Forecast $116.94M), Actual EPS -$0.7317 (Forecast -$0.975)

Inotiv released FY2024 Annual Earnings on December 3 After-Market (EST), Actual Revenue 490.74M USD (Forecast 477.25M USD), Actual EPS -4.19 (Forecast -4.435)

Mega Fortune

Processa Pharmaceuticals

Agape ATP

VYNE Therapeutics

cbdMD

Inspirato

Medline Inc.

Globavend

Beneficient

Andersen

Niagen Bioscience

ChromaDex

安捷倫科技

沃特世

西氏醫藥服務

藥明生物(ADR)

Medpace控股

Repligen

Stevanato Group SpA

Cryoport

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap